Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Coherus Oncology, Inc. (CHRS)

Coherus reports interim tagmokitug data, with 75% first-line ESCC response rate

Mixed Impact 4 of 5 other Written later

Coherus Oncology said on October 28, 2026 that interim data from its TREGCHECK program showed a confirmed overall response rate of 75% (6 of 8 evaluable patients) in first-line esophageal squamous cell carcinoma (ESCC) with tagmokitug, toripalimab and chemotherapy. The company plans to expand enrollment in both first-line and second-line ESCC cohorts, but the sample sizes are small and the drug is investigational and not approved.

Key points

  • First-line ESCC: confirmed overall response rate of 75% (6/8) as of October 14, 2026, rising to 89% (8/9) after two additional partial responses were confirmed following the data cutoff
  • Second-line ESCC at the 700 mg dose: clinical benefit rate of 33.3% (2/6) and confirmed overall response rate of 16.7% (1/6)
  • Safety: among 120 patients on tagmokitug plus toripalimab, 40% had immune-related adverse events of any grade and 20% had Grade 3-5 events; no Grade 5 treatment-related adverse events were reported

The filing

CompanyCoherus Oncology, Inc. (CHRS)
Form8-K, current report
Filed with the SECOct 29, 2026, 8:10 AM ET
Accession number0001104659-26-119912

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.